Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-drug interaction study of KBP-5074 with CYP3A4 inhibitor and inducer in healthy volunteers
NCT04606537Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ocederenone (2 cohorts), sponsored by KBP Biosciences. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-Time Curve from Time 0 to Infinity and 1 more. Started Oct 2020; status: completed.
02
Drugs
ocederenone
Beyond the preview
Go deeper on NCT04606537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606537.